Patents by Inventor Henrik Stephensen

Henrik Stephensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Acylated GLP-1 Compounds
    Publication number: 20120295847
    Abstract: Protracted GLP-1 compounds and therapeutic uses thereof.
    Type: Application
    Filed: March 5, 2012
    Publication date: November 22, 2012
    Applicant: Novo Nordisk A/S
    Inventors: Jesper Lau, Florencio Zaragoza Dörwald, Henrik Stephensen, Paw Bloch, Thomas Kruse Hansen, Kjeld Madsen
  • Novel Aryl- and Heteroarylpiperazines
    Publication number: 20090264435
    Abstract: Novel aryl- and heteroarylpiperazines, use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds, and a method of treatment employing these compounds and compositions. The compounds show a high and selective binding affinity to the histamine H3 receptor indicating histamine H3 receptor antagonistic, inverse agonistic or agonistic activity. As a result, the compounds are useful for the treatment of diseases and disorders related to the histamine H3 receptor.
    Type: Application
    Filed: February 9, 2009
    Publication date: October 22, 2009
    Applicant: High Point Pharmaceuticals, LLC
    Inventors: Rolf Hohlweg, Florencio Zaragoza Dorwald, Henrik Stephensen, Ingrid Pettersson, Bernd Peschke
  • Acylated GLP-1 Compounds
    Publication number: 20090156478
    Abstract: Protracted GLP-1 compounds and therapeutic uses thereof.
    Type: Application
    Filed: March 20, 2006
    Publication date: June 18, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Jesper Lau, Florencio Zaragoza Dorwald, Henrik Stephensen, Paw Bloch, Thomas Kruse Hansen, Kjeld Madsen
  • Novel aryl- and heteroarylpiperazines
    Publication number: 20030236259
    Abstract: Novel aryl- and heteroarylpiperazines, use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds, and a method of treatment employing these compounds and compositions. The compounds show a high and selective binding affinity to the histamine H3 receptor indicating histamine H3 receptor antagonistic, inverse agonistic or agonistic activity. As a result, the compounds are useful for the treatment of diseases and disorders related to the histamine H3 receptor.
    Type: Application
    Filed: March 7, 2003
    Publication date: December 25, 2003
    Inventors: Rolf Hohlweg, Florencio Zaragoza Dorwald, Henrik Stephensen, Ingrid Pettersson, Bernd Peschke